Journal of Multiple Sclerosis and Neuroimmunology 12(2):39-42, 2021
Successful Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy with Rituximab
Dayoung Kim, MD, Kyomin Choi, MD, Jeeyoung Oh, MD, PhD
Department of Neurology, Konkuk University Medical Center, Seoul, Korea
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a heterogeneous autoimmune disease characterized by a relapsing and remitting or progressive pattern. Corticosteroid, intravenous immunoglobulin or plasma exchange are usually used as treatment options. However, approximately one-third of patients with CIDP have an inadequate response to standard treatments. Rituximab, a monoclonal antibody against CD20, has been used with good results in some patients with refractory CIDP. We report a patient with refractory CIDP in whom remission has been successfully maintained after treatment with rituximab.
Journal of Multiple Sclerosis and Neuroimmunology 12(2):39-42, 2021
